NEW DRUG LECANEMAB Q&A

Please refer to alzheimer.ca/Lecanemab for updated information.
Q: What is Lecanemab?
A: Lecanemab (brand name Leqembi) is a drug specifically for people with mild cognitive impairment or the mild dementia stage of Alzheimer’s disease – not for people at moderate or later stages. Lecanemab is not a cure, but can slow the progression of Alzheimer’s disease.
Q: How long will it take for Health Canada to review the drug and make a decision?
A: Health Canada began reviewing Lecanemab in May 2023. Their website explains that timing can vary depending “on the product being submitted and the size and quality of the submission, and is influenced by [our] workload and human resources.”
Q: Can people in Canada use Lecanemab?
A: In Canada, the drug is not available outside of experimental drug trials. Ask your doctor, neurologist or dementia specialist about trials or studies in Canada or visit alzheimer.ca/find-studies
